NSC
47
-3
BF.B
31
2
HES
62
4
AMGN
47
8
TAP
51
6
AMG
22
-16
OXY
53
4
SEE
45
-4
NOV
52
3
CAT
55
-2
MCD
52
-2
LB
30
-8
CNP
44
8
XRAY
34
11
MOS
48
6
A
47
6
VFC
65
2
HBI
50
-2
MAT
62
2
PEP
47
3
NSC
47
-3
BF.B
31
2
HES
62
4
AMGN
47
8
TAP
51
6
AMG
22
-16
OXY
53
4
SEE
45
-4
NOV
52
3
CAT
55
-2
MCD
52
-2
LB
30
-8
CNP
44
8
XRAY
34
11
MOS
48
6
A
47
6
VFC
65
2
HBI
50
-2
MAT
62
2
PEP
47
3
Financhill
Back

Ocular Therapeutix Quote, Financials, Valuation and Earnings

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade
Buy
54

OCUL
Ocular Therapeutix

Last Price:
10.24
Seasonality Move:
21.32%

7 Day Trial

ALL ACCESS PASS

$ 7

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!

Ocular Therapeutix Price Quote

$10.24
-0.03 (-1.44%)
(Updated: November 5, 2024 at 5:36 AM ET)

Ocular Therapeutix Key Stats

Buy
54
Ocular Therapeutix (OCUL) is a Buy
Day range:
$9.76 - $10.51
52-week range:
$2.00 - $11.78
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
19.89
P/B ratio:
4.24%
Volume:
1.1M
Avg. volume:
1.3M
1-year change:
215.03%
Market cap:
$1.6B
Revenue:
$58.4M
EPS:
$-1.35

How Much Does Ocular Therapeutix Make?

Is Ocular Therapeutix Growing As A Company?

  • What Is Ocular Therapeutix's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.08%
  • What Is Ocular Therapeutix's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Ocular Therapeutix Stock Price Performance

What Is Ocular Therapeutix 52-Week High & Low?

Ocular Therapeutix Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Ocular Therapeutix?

  • How Much Debt Does Ocular Therapeutix Have?
    Total long term debt quarterly is $67.1M
  • How Much Cash Does Ocular Therapeutix Have?
    Cash and short term investments quarterly total is $459.7M
  • What Is Ocular Therapeutix’s Book Value Per Share?
    Book value per share is 2.43

Is Ocular Therapeutix Cash Flow Positive?

  • What Is OCUL Cash Flow From Operations?
    Cash flow from operations (TTM) is -$88.9M
  • What Is Ocular Therapeutix’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $483.5M
  • What Is Ocular Therapeutix’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$1.7M

Ocular Therapeutix Return On Invested Capital

  • Is Management Doing A Good Job?
    OCUL return on invested capital is -56.45%
  • What Is Ocular Therapeutix Return On Assets?
    ROA measures how assets are converting to revenues and is -43.43%
  • What Is OCUL Return On Equity?
    ROE is a measure of profitability and is -77.93%

Ocular Therapeutix Earnings Date & Stock Price

Ocular Therapeutix Competitors

  • Who Are Ocular Therapeutix's Competitors?
    Below is a list of companies who compete with Ocular Therapeutix or are related in some way:
    • 4D Molecular Therapeutics Inc (FDMT)
    • Lyell Immunopharma Inc (LYEL)
    • Marinus Pharmaceuticals Inc (MRNS)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)

Ocular Therapeutix Dividend Yield

Ocular Therapeutix Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -21.88%
Revenue: 8.26% 3.75%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 16.56
Upside from Last Price: 61.2%

Major Shareholders

  • How many OCUL shares are owned by institutional investors?
    184.9M OCUL shares are owned by institutional investors
  • How many OCUL shares are owned by insiders?
    4.9M OCUL shares are owned by insiders